NKG2A

Class

Anti-NKG2A monoclonal antibody (fully human IgG1)

Pathway

Immune checkpoint blockade releasing NK-cell and T-cell inhibition

NKG2A is an inhibitory receptor expressed on natural killer (NK) cells and a subset of cytotoxic CD8+ T cells. It pairs with CD94 to form a heterodimer that recognizes HLA-E, a non-classical major histocompatibility complex molecule that many tumors and virally infected cells upregulate as a way to blunt immune attack. When NKG2A engages HLA-E, it delivers an inhibitory signal that dampens the killing activity of NK cells and limits cytotoxic T-cell function. Antibodies that block NKG2A prevent this interaction, releasing the brakes on both arms of the immune system simultaneously, which distinguishes this approach from checkpoint blockade strategies that act on T cells alone. This dual engagement is biologically appealing in cancers where tumors exploit HLA-E to escape immune surveillance, and it may also have relevance in chronic viral infections where NK and T-cell exhaustion contribute to persistence. Because NKG2A blockade operates through a distinct receptor-ligand pair from PD-1/PD-L1 or CTLA-4, it represents a complementary route to immune checkpoint modulation, one that could in principle be paired with other immune-stimulating approaches, including antibodies that depend on NK-cell-mediated killing.